Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit. This provides a new avenue toward eliminating the need to keep some vaccines and antibiotics refrigerated, which could save billions of dollars every year and increase accessibility to third world populations.
Vaccines and antibiotics often need to be refrigerated to prevent alteration of their chemical structures; such alteration can result in less potent or ineffective medications. By immobilizing their bioactive molecules using silk protein matrices, researchers were able to protect and stabilize both live vaccines and antibiotics when stored at higher than recommended temperatures for periods far longer than recommended.
The research was led by grantees of NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB), David Kaplan, PhD, and Jeney Zhang, PhD candidate, at Tufts University School of Engineering in Medford, Mass. The National Eye Institute and the National Institute of Dental and Craniofacial Research at NIH also contributed to this research. The researchers reported on their findings in the online issue of Proceedings of the National Academy of Sciences on July 9, 2012.
"This truly exciting development is the culmination of years of creative exploration and research focused on a major problem in the delivery of health care. Dr. Kaplan and his team have done a masterful job at both understanding the key properties of silk, and applying these insights to a global medical challenge," says NIBIB director Roderic I. Pettigrew, PhD, MD. "This is also a wonderful validation of the type of team science we see in our Biotechnology Resource and Development Centers and their ability to combine cutting edge science in a number of fields to a variety of health needs."
Pettigrew also points out that the next step is to test it in the field.
Keeping medications cold from production until they are used in treatment is a costly process, accounting for as much as 80 percent of the price of vaccinations. The need for a cold chain has been a difficulty for healthcare providers, aid organizations, scientists and pharmaceutical companies for decades, especially in settings where electricity is limited. Failures in the chain result in the loss of nearly half of all global vaccines, according to researchers.
In an attempt to solve this problem, Kaplan and his lab have been working extensively with silk films that essentially wrap up the live bioactive molecules present in antibiotics and vaccines. This protects these essential bioactive elements, and so can greatly extend the shelf-life of the medication. Silk is used because it is a protein polymer with a chemistry, structure, and assembly that can generate a unique environment, making it an attractive candidate for the stabilization of bioactive molecules over extended periods of time.
To test their new silk stabilizers, Kaplan's team stored the measles, mumps, and rubella (MMR) vaccines for six months at the recommended 39.2 degrees Fahrenheit, as well as at 77, 98.6 , and 113 degrees Fahrenheit. The results show that encapsulation in the new silk films maintained the potency with minimal loss over time and enhanced stability, even at very high storage temperatures. Similarly, antibiotics entrapped in silk films maintained near optimal activity even at temperatures as high as 140 degrees. In addition, Kaplan's group found that these silk films had the added benefit of protecting one antibiotic against the detrimental effects of light exposure.
The silk stabilizers are likely to combine well with Kaplan's previously developed silk microneedle system. These tiny needles can deliver medication directly to skin cells that contain a specified antigen. This targeted approach permits administration of lower doses of medication or vaccine and generates longer-lasting immune responses. The combination could prove to be a simple way to stabilize, distribute, and deliver the medication in one system.
 Thus, for vaccines and antibiotics, the use of a silk carrier reduces the detrimental effects of heat and humidity.
"New studies are already under way," says Kaplan. "We have already begun trying to broaden the impact of what we're doing to apply to all vaccines. Based on what we've seen with other proteins, peptides, and enzymes, there's no reason to believe that this wouldn't be universal. This could potentially eliminate the need for a cold-chain system, greatly decreasing costs and enabling more widespread availability of these life-saving drugs."
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.